Sitagliptin added to treatment with ongoing pioglitazone for up to 52?weeks improves glycemic control in Japanese patients with type?2 diabetes.

ABSTRACT: Aims/Introduction:? Patients with type?2 diabetes mellitus often require treatment with more than one oral antihyperglycemic agent to achieve their glycemic goal. The present study was carried out to assess the efficacy and safety of sitagliptin as add-on therapy in Japanese patients with type?2 diabetes mellitus inadequately controlled (HbA1c???6.9% and <10.4%) on pioglitazone monotherapy (15-45?mg/day).? In the initial 12-week, double-blind treatment period, patients were randomized (1:1) to sitagliptin 50?mg/day (n?=?66) or placebo (n?=?68), followed by a 40-week open-label treatment period in which all patients received sitagliptin 50?mg/day that could have been increased to 100?mg/day for patients meeting predefined glycemic parameters.? After 12?weeks, mean changes from baseline in HbA1c (the primary end-point), fasting plasma glucose and 2-h post-meal glucose were -0.8%, -0.9?mmol/L and -2.7?mmol/L, respectively, in the sitagliptin group compared with placebo (all P?

SUBMITTER: Kashiwagi A 

PROVIDER: S-EPMC4019307 | biostudies-literature | 2011 Oct

REPOSITORIES: biostudies-literature